Home pageATHA • NASDAQ
add
Athira Pharma
0,30 $
After Hours:(0,34%)+0,0010
0,30 $
Data e ora chiusura: 27 giu, 20:00:00 GMT-4 · USD · NASDAQ · Disclaimer
Chiusura precedente
0,30 $
Intervallo giornaliero
0,30 $ - 0,32 $
Intervallo annuale
0,22 $ - 3,67 $
Cap di mercato
11,63 Mln USD
Volume medio
939.214,00
Rapporto P/E
-
Dividendo/Prezzo
-
Borsa valori principale
NASDAQ
Notizie del mercato finanziario
Dati finanziari
Conto economico
Entrate
Utile netto
| (USD) | mar 2025info | Variazione Y/Y |
|---|---|---|
Entrate | — | — |
Spese di gestione | 9,54 Mln | -65,56% |
Utile netto | -9,14 Mln | 65,28% |
Margine di profitto netto | — | — |
Utili per azione | — | — |
EBITDA | -9,29 Mln | 66,14% |
Aliquota fiscale effettiva | — | — |
Stato patrimoniale
Totale attivo
Totale passivo
| (USD) | mar 2025info | Variazione Y/Y |
|---|---|---|
Investimenti cash/breve termine | 36,67 Mln | -69,96% |
Totale attivo | 43,51 Mln | -67,40% |
Totale passivo | 6,18 Mln | -76,86% |
Patrimonio netto totale | 37,33 Mln | — |
Azioni in circolazione | 39,04 Mln | — |
Prezzo/valore contabile | 0,32 | — |
Redditività dell'attivo | -46,61% | — |
Rendimento sul capitale | -56,42% | — |
Flusso di cassa
Flusso di cassa netto
| (USD) | mar 2025info | Variazione Y/Y |
|---|---|---|
Utile netto | -9,14 Mln | 65,28% |
Liquidità di esercizio | -14,66 Mln | 43,17% |
Contanti da investimenti | -7,35 Mln | -156,37% |
Contanti da finanziamenti | — | — |
Flusso di cassa netto | -22,02 Mln | -72,50% |
Flusso di cassa libero | -11,35 Mln | 32,75% |
Informazioni
Athira Pharma is a late clinical stage American biopharmaceutical company developing small molecules to restore neuronal health and stop the neurodegeneration brought on by diseases such as Alzheimer's disease and Parkinson's disease. The company's lead candidate, ATH-1017, is in human studies for Alzheimer's disease as of 2021.
The company was founded in 2011 and is headquartered in Seattle. Funding that supports the company is from both public and private investment groups including the Alzheimer's Drug Discovery Foundation, Dolby Family Ventures, the State of Washington's Life Sciences Discovery Fund, The W Fund, WRF Capital, and other private investors.
Leen Kawas served as the company's first President and CEO, but resigned in October 2021, after an independent special committee found she "altered images in scientific papers she authored." In 2025, the company paid a $4 million settlement in relation to allegations that the CEO falsified research to secure a federal grant. On October 21, 2021, Mark Litton, Ph.D., M.B.A. became chief executive officer. Wikipedia
Fondazione
2011
Sito web
Dipendenti
26
